Press Releases

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

All News | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |

Nov 10, 2021

TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 01, 2021

TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity

Oct 25, 2021

TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors

Oct 20, 2021

TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day

Oct 13, 2021

TCR² Therapeutics to Host R&D Day on October 20, 2021

Oct 05, 2021

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

Sep 17, 2021

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

Sep 13, 2021

TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors

Sep 07, 2021

TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Sep 02, 2021

TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma